Last reviewed · How we verify
TDF Intravaginal Ring
At a glance
| Generic name | TDF Intravaginal Ring |
|---|---|
| Also known as | TDF IVR |
| Sponsor | Albert Einstein College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir (PHASE1)
- PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) (EARLY_PHASE1)
- Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring (PHASE2)
- The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)
- Safety, PK, and PD Study of IVRs Releasing TFV and LNG (PHASE1)
- Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women (EARLY_PHASE1)
- Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (PHASE1)
- Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDF Intravaginal Ring CI brief — competitive landscape report
- TDF Intravaginal Ring updates RSS · CI watch RSS
- Albert Einstein College of Medicine portfolio CI